Axogen Inc (AXGN)

Currency in USD
32.29
+1.60(+5.21%)
Closed·
32.00-0.29(-0.90%)
·
AXGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.0132.29
52 wk Range
9.2236.00
Key Statistics
Prev. Close
32.29
Open
30.43
Day's Range
30.01-32.29
52 wk Range
9.22-36
Volume
845.91K
Average Volume (3m)
916.9K
1-Year Change
85.043%
Book Value / Share
2.79
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AXGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.56
Upside
+25.60%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period

Axogen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Axogen Inc SWOT Analysis


Nerve Repair Pionee
AxoGen leads in peripheral nerve injury solutions, with a growing $5.6 billion market and innovative products driving expansion into new segments like prostate care
Financial Resilience
Q1 2025 revenue of $48.6M, up 17.4% YoY. Full-year guidance of $215.4M-$219.1M reaffirmed, projecting 15-17% growth. Analysts forecast $248M by 2026
Regulatory Catalyst
Anticipated BLA approval for Avance Nerve Graft in September 2025 could boost adoption, secure market exclusivity, and establish it as the standard of care
Strategic Vision
New CEO Michael Dale's seven-point plan aims for cash flow positivity by 2025-2028, with $70M+ annual operational cash flow by 2028, self-funding future growth
Read full SWOT analysis

Axogen Inc Earnings Call Summary for Q4/2025

  • AxoGen Q4 2025 adjusted EPS of $0.07 beat forecast of $0.06; revenue reached $59.9M vs. expected $58.25M, up 21.3% YoY driven by Avance sales.
  • Stock declined 6.73% to $33 in pre-market despite earnings beat, as operating expenses surged 52.3% to $54.2M due to non-cash stock compensation.
  • Gross margin compressed to 74.1% from 76.1% YoY; full-year 2025 revenue rose 20.2% compared to 2024, reflecting strong product demand.
  • FY2026 guidance projects quarterly EPS of $0.07-$0.19 and full-year revenue of $259.6M; analysts expect profitability despite recent margin pressures.
  • CEO cited strategic initiatives positioning company for growth, while acknowledging temporary margin headwinds from Avance biologic processing transition.
Last Updated: 2026-02-24, 09:18 a/m
Read Full Transcript

Compare AXGN to Peers and Sector

Metrics to compare
AXGN
Peers
Sector
Relationship
P/E Ratio
−106.7x−3.9x−0.5x
PEG Ratio
2.070.010.00
Price/Book
13.0x3.5x2.6x
Price / LTM Sales
7.4x3.4x3.2x
Upside (Analyst Target)
23.9%42.6%49.3%
Fair Value Upside
Unlock10.0%6.3%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 40.56
(+25.60% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy42.00+30.07%-MaintainFeb 25, 2026
Citizens
Sell42.00+30.07%34.00MaintainFeb 24, 2026
Wells Fargo
Buy40.00+23.88%-New CoverageFeb 19, 2026
Canaccord Genuity
Buy40.00+23.88%37.00MaintainFeb 02, 2026
Canaccord Genuity
Buy37.00+14.59%-MaintainJan 13, 2026

Earnings

Latest Release
Feb 24, 2026
EPS / Forecast
0.07 / 0.06
Revenue / Forecast
59.90M / 58.25M
EPS Revisions
Last 90 days

AXGN Income Statement

People Also Watch

28.79
HRMY
+0.17%
50.92
PARR
+6.02%
14.930
AMLX
-0.33%
91.75
MIRM
+0.90%
13.640
NPKI
-2.08%

FAQ

What Is the Axogen Inc (AXGN) Stock Price Today?

The Axogen Inc stock price today is 32.29 USD.

What Stock Exchange Does Axogen Inc Trade On?

Axogen Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Axogen Inc?

The stock symbol for Axogen Inc is "AXGN."

What Is the Axogen Inc Market Cap?

As of today, Axogen Inc market cap is 1.68B USD.

What Is Axogen Inc's Earnings Per Share (TTM)?

The Axogen Inc EPS (TTM) is -0.34.

When Is the Next Axogen Inc Earnings Date?

Axogen Inc will release its next earnings report on May 06, 2026.

From a Technical Analysis Perspective, Is AXGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Axogen Inc Stock Split?

Axogen Inc has split 0 times.

How Many Employees Does Axogen Inc Have?

Axogen Inc has 622 employees.

What is the current trading status of Axogen Inc (AXGN)?

As of Mar 12, 2026, Axogen Inc (AXGN) is trading at a price of 32.29 USD, with a previous close of 32.29 USD. The stock has fluctuated within a day range of 30.01 USD to 32.29 USD, while its 52-week range spans from 9.22 USD to 36.00 USD.

What Is Axogen Inc (AXGN) Price Target According to Analysts?

The average 12-month price target for Axogen Inc is 40.56 USD, with a high estimate of 43 USD and a low estimate of 39 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +25.60% Upside potential.

What Is the AXGN Premarket Price?

AXGN's last pre-market stock price is 32.00 USD. The pre-market share volume is 1,380.00, and the stock has decreased by -0.29, or -0.90%.

What Is the AXGN After Hours Price?

AXGN's last after hours stock price is 32.36 USD, the stock has decreased by 0.07, or 0.22%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.